Monopar Therapeutics (MNPR) Net Income towards Common Stockholders (QoQ) (2017 - 2025)
Monopar Therapeutics (MNPR) Net Income towards Common Stockholders (QoQ) (2017 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Monopar Therapeutics | 800.03 Mn | 738.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -65.64% |
| Jun 30, 2025 | 19.99% |
| Sep 30, 2024 | 17.40% |
| Jun 30, 2024 | -4.82% |
| Sep 30, 2023 | 16.81% |
| Jun 30, 2023 | 5.74% |
| Mar 31, 2023 | 81.44% |
| Dec 31, 2022 | -456.70% |
| Sep 30, 2022 | 15.36% |
| Jun 30, 2022 | -15.69% |
| Mar 31, 2022 | 76.33% |
| Dec 31, 2021 | -322.99% |
| Sep 30, 2021 | -17.52% |
| Jun 30, 2021 | -10.43% |
| Mar 31, 2021 | 74.67% |
| Dec 31, 2020 | -353.94% |
| Sep 30, 2020 | -12.56% |
| Jun 30, 2020 | -28.88% |
| Mar 31, 2020 | 70.05% |
| Dec 31, 2019 | -394.50% |